PETACH TIKVA, Israel – Can-Fite BioPharma (NYSE:) Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company specializing in the development of small molecule drugs, has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent related to its drug Namodenoson.
The patent covers the use of Namodenoson in treating ectopic fat accumulation, specifically in reducing liver fat in patients with non-alcoholic steatohepatitis (NASH).
Namodenoson has shown promise in a Phase IIa study by reducing liver fat content, decreasing body weight, and showing anti-inflammatory effects in NASH patients. The drug is now enrolling patients for a Phase IIb study, with liver pathology as the primary endpoint, aiming to include 140 patients.
Dr. Ilan Cohn, Can-Fite founder and a patent attorney, highlighted the significance of the Canadian patent, which complements the company’s intellectual property portfolio for Namodenoson in addressing fatty liver disease. This addition to their IP estate aligns with positive Phase IIa data and the drug’s safety profile, positioning it as a viable treatment option.
Namodenoson operates by selectively binding to the A3 adenosine receptor (A3AR), which is highly expressed in diseased cells, potentially contributing to its favorable safety profile. The compound is also being evaluated in a pivotal Phase III trial for advanced liver cancer and is planned for a Phase IIa study in pancreatic cancer.
Can-Fite has out-licensed Namodenoson for NASH treatment in Eastern Europe to Ewopharma, in China, Hong Kong, and Macau to CMS China, and in South Korea to CKD. Additionally, Can-Fite has a distribution agreement in Canada for Piclidenoson, another of its drug candidates, for the treatment of psoriasis.
The NASH market is projected to reach $24 billion by 2028, with non-alcoholic fatty liver disease affecting 30-40% of adults in the U.S., making it one of the most common causes of liver disease in the country.
The information presented in this article is based on a press release statement from Can-Fite BioPharma Ltd.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here